[Translation] A multicenter, randomized, double-blind, placebo-controlled phase I clinical trial evaluating the safety, tolerability and pharmacokinetics of ALMB-0166 in patients with acute spinal cord injury
主要研究目的是在急性脊髓损伤患者中评价ALMB-0166单次给药的安全性和耐受性。次要研究目的包括评价ALMB-0166单次给药的药代动力学特征、初步疗效和免疫原性。
[Translation] The primary study objective was to evaluate the safety and tolerability of a single dose of ALMB-0166 in patients with acute spinal cord injury. Secondary study objectives include evaluating the pharmacokinetic profile, preliminary efficacy and immunogenicity of a single dose of ALMB-0166.